Rubicon Research

Rubicon has developed several proprietary drug delivery technologies with secured IP protection such as ✓RubiERT, ✓RubiReten, ✓RubiSRL, ✓RubiDT. Rubicon’s experience involves working with Barrier membrane technology, Matrix systems and Osmotic systems.

Rubicon develops pharmaceutical products using expertise and resources.

Rubicon has developed and scaled up several prescription medicines. Several of these products have been commercialized from third party manufacturing sites across the world.

Intimations filed with the stock exchanges under Regulation 30.

The page offers Rubicon’s latest press releases, updates, videos, and downloadable images.

The Rubicon leadership team has a synergistic composition of working directors, each with a specialization that has withstood the toughest tests of result-oriented international business environment.

Rubicon’s ‘Grow Together’ initiative provides capital and strategic support to seed and early-stage ventures in pharmaceuticals and allied domains, including AI, continuous manufacturing, and big data.

Rubicon Research integrates social responsibility into its workplace culture and community engagement through Sankalp, an employee platform for CSR initiatives.

Investor information for Rubicon Research Limited, including financial results, corporate announcements, policies, and disclosures under Regulation 46 of SEBI (LODR) Regulations, 2015.

Rubicon is a partner of choice in developing and bring to market value added pharmaceutical (Rx, OTC and Consumer) products.

Rubicon provides customer support.

Registrar and Share Transfer Agent, Compliance Officer, and grievance redressal.

Rubicon has built and expanded on strong strategic partnerships primarily regarding Development, Manufacturing, and Regulatory Support of Pharmaceutical Products.